Floatz logo

pf-05212384

Prostatic Neoplasms, Castration-Resistant

Celcuity IncPhase 1/2Active
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

23 Active assets in the Prostatic Neoplasms, Castration-Resistant cohort.

Asset / SponsorPhaseRating
RADIUM RA-223
University of California, San Francisco
Phase 4BB
Atezolizumab
Cancer Research UK
Phase 3BB
Fluciclovine
VA Greater Los Angeles Healthcare System
Phase 4B
tqb3616
West China Hospital
Phase 2CCC
Jnj-809
Janssen Research & Development, LLC
Phase 2CCC

View all 29 →

Same molecule, other indications

pf-05212384 is also rated in:

breast cancerDormant
CCC
Indicative ·
54 / 100
View asset →
therapy-related myeloid neoplasmDormant
CCC
Indicative ·
50 / 100
View asset →
acute myeloid leukemiaDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →